Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
IOVA holding history
Iovance Biotherapeutics, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
IOVA overviewAll 13F holders of IOVAFull Q2 2026 holdings
- Shares (Q2 2026)
- 39,491
- Value
- $164.3K
- % of portfolio
- <0.1%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 39,491 | $164.3K | <0.1% | −2,316,121−98.3% | Reduced | Holders |
| Q1 2026 | 2,355,612 | $8.27M | <0.1% | +2,355,612 | New | Holders |
| Q3 2025 | 0 | $0 | 0.0% | −111,200−100.0% | Sold out | Holders |
| Q2 2025 | 111,200 | $191.3K | <0.1% | +71,558+180.5% | Added | Holders |
| Q1 2025 | 39,642 | $132.0K | <0.1% | −1,090,813−96.5% | Reduced | Holders |
| Q4 2024 | 1,130,455 | $8.37M | <0.1% | +1,130,455 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −1,612,055−100.0% | Sold out | Holders |
| Q2 2024 | 1,612,055 | $12.9M | <0.1% | +1,612,055 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −35,011−100.0% | Sold out | Holders |
| Q3 2023 | 35,011 | $159.3K | <0.1% | +35,011 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −369,463−100.0% | Sold out | Holders |
| Q4 2022 | 369,463 | $2.36M | <0.1% | +369,463 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −50,953−100.0% | Sold out | Holders |
| Q1 2022 | 50,953 | $848.0K | <0.1% | −810,207−94.1% | Reduced | Holders |
| Q4 2021 | 861,160 | $16.4M | <0.1% | +861,160 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −17,867−100.0% | Sold out | Holders |
| Q2 2021 | 17,867 | $465.0K | <0.1% | −23,932−57.3% | Reduced | Holders |
| Q1 2021 | 41,799 | $1.32M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.